colorectal cancer
Conditions
Interventions
S-1 : day1-14 80mg/m2. CPT-11 : day1 150mg/m2 Cetuximab : day1,8,15 400mg/m2 (1st time) , 250mg/m2 (2nd time or another) to be repeated every 3 weeks
Sponsors
Nippon Medical School Musashikosugi Hospital
Nippon Medical School Hospital Nippon Medical School Tama Nagayama Hospital Nippon Medical School Chiba Hokusoh Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically confirmed colorectal cancer 2) Unresectable advanced/recurrent colorectal cancer 3) Age between 20 to 80 years 4) ECOG performance status 0-1 5) Presence of measurable lesion (RECIST) 6) Prior chemotherapy involving L-OHP 7) No prior chemotherapy involving CPT-11 or Cetuximab 8) Sufficient organ functions 9) The case can eat 10) Written informed consent
Exclusion criteria
Exclusion criteria: 1) History of severe allergy 2) Simultaneous or metachronous double cancers 3) active infectious disease, 4) Severe comorbidity 5) Massive pleural effusion or ascites 6) Wattery diarrhea 7) Paralytic or mechanical bowel obstruction 8) Symptomatic brain metastasis 9) Patients who is receiving Fluorocytosine or Atazanavir Sulfate 10) Pregnant or lactating women or women of childbearing potential. 11) Amalgamation of mental disease or psychotic manifestation 12) Patients who are inadequate by investigator's decision.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| progression free survival overall survival disease control rate re-resection rate adverse event dose intensity | — |
Countries
Japan
Contacts
Public ContactHideyuki Suzuki
Nippon Medical School Musashikosugi Hospital Institute of Gastroenterology
Outcome results
None listed